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Chronic myeloid leukemia (CML), as most of cancers results from a complex interaction between genetic or non
genetic factors. Exposures to xenobiotics endogenous or exogenous associated with a reduced individual ability in
detoxifying activity, constitutes a risk of developing cancer. It is known that polymorphism of glutathione S-transferases
(GSTs) genes affects the detoxification of xenobiotics. Thus, we conducted a case-control study in which 92 patients
(Mean age ± SD, 40.62 ± 12.7 years) with CML and 93 healthy unrelated controls (Mean age ± SD, 41.38 ± 13.4 years)
have participated. GSTM1 and GSTT1 genotypes were determined by multiplex polymerase chain reaction. Logistic
regression was used to assess the possible link between GSTM1 and GSTT1 null genotypes and CML as well as between
combined genotypes and CML. GSTM1 null genotype frequency was slightly higher in patients than control (48.9%
vs. 40.9%) but, it was not associated with CML (OR 95% CI, 1.4, 0.78-2.48; p = 0.271). Moreover, GSTT1 null genotype
frequency showed a similar trend between patients and control (17.4% vs. 9.7%; OR 95% CI, 1.97, 0.82-4.71; p = 0.13).
Surprisingly, GSTT1 null genotype was significantly associated with the risk of CML in males (OR 95% CI, 5, 1.25-20.1;
p = 0.023). The combined GSTM1 present/GSTT1 null genotype was found to have a limited effect against the risk of
CML (OR 95% CI, 0.3, 0.08-0.99; p = 0.049). Our findings have shown that GSTT1 null genotype might be a risk factor of
CML in males. While, GSTT1 present genotype might be considered as protective against CML. However, further studies
with a large sample size are needed to confirm our findings.
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Chronic myeloid leukemia (CML) is a blood cancer sec-
ondary to the presence of the reciprocal translocation
t(9; 22)(q34; q11) or BCR-ABL gene fusion causing a
malignant proliferation of hematopoietic cells (Deininger
et al. 2000). However, The etiology of CML like most of
cancers, results from a complex interaction between sev-
eral factors, among others exposure to ionizing and non
ionizing radiation, carcinogens present in the environ-
ment such as benzene, smoke and pesticides (Salagovic
et al. 2000; Gervasini et al. 2007). These factors consid-
ered as genotoxics may affect the biotransformation of xe-
nobiotics and cause damage to the DNA of hematopoietic
cells and foster the occurrence of CML (Belitsky &
Yakubovskaya 2008). Obviously, depending to the genetic
constitution on the individual level, the body prevents* Correspondence: nadifi@labgenmed.com
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in any medium, provided the original work is psuch damage, thanks to enzymes which play a major role
in the activation/detoxification of carcinogens, repair of
DNA damage and programming of mutant cells to apop-
tosis (Belitsky & Yakubovskaya 2008; Hayes and Pulford
1995; Fang et al. 2013). It is noteworthy that hereditary dif-
ferences which affect an individual’s ability to metabolize
xenobiotics represent significant factors in predisposition
to develop cancer such as CML (Taioli 1999; Siraj et al.
2008). Glutathione S-transferases (GSTs) are enzymes of
phase II, which participate in cellular detoxification by
converting active procarcinogenic metabolites of phase I
enzymes (cytochrome P450) into inactive metabolites and
soluble glutathione, easily execretable. Nowadays, eight
classes of GSTs have been identified, including alpha
(GSTA), mu (GSTM) theta (GSTT), pi (GSTP), zeta
(GSTZ), sigma (GSTS), kappa (GSTK) and omega (GSTO)
(Mannervik et al. 1992). Among these, GSTM1 and
GSTT1 genes which have been mapped on chromosome
1p13.3 and 22q11.2 respectively, are the most studied
(Pearson et al. 1993; Webb et al. 1996). It is known thatis an Open Access article distributed under the terms of the Creative Commons
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roperly credited.
Table 1 Distribution of GSTM1 and GSTT1 genotypes
between patients and control and evaluation of the risk
of CML
GST polymorphism Patients Control OR P value
N (%) N (%) 95% CI
GSTM1
Present 47 (51.1) 55 (59.1) 1
Null 45 (48.9) 38 (40.9) 1.4 (0.78-2.48) 0.271
GSTT1
Present 76 (82.6) 84 (90.3) 1
Null 16 (17.4) 9 (9.7) 1.97 (0.82-4.71) 0.13
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reduced or absence of enzyme activity (Hallier et al. 1993).
Moreover, numerous studies have shown the link between
the lack of enzyme activity in GSTM1 and GSTT1 and the
susceptibility to develop various types of cancer, such as
oral cancer, gastric cancer, bladder cancer, and CML in dif-
ferent ethnical groups worldwide (Bajpai et al. 2007;
Sharma et al. 2013; Dunna et al. 2013; Ma et al. 2013;
Dong et al. 2013; Bhat et al. 2012). Furthermore, other
studies have found an association between GSTM1 and
GSTT1 deletions and the response to chemotherapy,
such as disease free survival, overall survival or toxicity
(Voso et al. 2002; Mossallam et al. 2006). Given the ab-
sence of data on the frequencies of GSTM1 and GSTT1
genotypes in our population, we decided to carry out
this case-control study with the aim to establish firstly
their frequencies in the population and secondly esti-
mate the possible link between the null genotypes and
the occurrence of chronic myeloid leukemia in a sample
of the Moroccan population.
Materials and methods
Subjects
This study was performed after approval of the local
Ethics Committee and individual informed consent from
patients and control. A total of 92 patients have partici-
pated. Patient’s selection was based on the presence of
clinically-hematologic signs and Philadelphia chromo-
some or BCR-ABL gene fusion (Baccarani et al. 2009).
Patients were recruited in the department of Onco-
Hematology of the Ibn Rochd University Hospital in
Casablanca, Morocco from 2011 to 2013. During the
same period 93 unrelated healthy controls without a
family history of cancer were recruited at the laboratory
of genetic and molecular diseases, Faculty of Medicine,
the Hassan II University in Casablanca. Four milliliters
of venous blood were collected in EDTA tube and kept
to minus 20°C till DNA extraction.
Genotyping of GSTM1 and GSTT1 polymorphism
Salting-out method was used to extract DNA from white
blood cells (Miller et al. 1988). GSTM1 and GSTT1 poly-
morphism were detected by using a multiplex polymer-
ase chain reaction (PCR) in which BCL2 gene as an
internal control was used. The PCR was carried out in a
mixture containing 100 ng of genomic DNA, 1X of 5X
GoTaq Flexi Buffer (Promega), 1.5 mM of MgCl2,
0.2 mM of each dNTP, 10 pM of each primer and 0.5 U
of GoTaq polymerase (Promega) completed to 25 μl with
molecular grade water. Forward and reverse primers
were 5’-TTCCTTACTGGTCCTCACATCTC-3’ and 5’-T
CACCGGATCATGGCCAGCA-3’ respectively, for GSTT1;
5'-GAACTCCCTGAAAAGCTAAAGC-3' and 5'- GTTGG
GCTCAAATATACGGTGG-3', respectively for GSTM1.Forward and reverse primers for BCL2 gene were 5'-G
CAATTCCGCATTTAATTCATGG-3' and 5'- GAAACAG
GCCACGTAAAGCAAC-3', respectively (Voso et al. 2002).
PCR amplification was performed with an initial denatur-
ation at 94°C for 5 minutes, followed by 35 cycles at 94°C
for 1 minute, 61°C for 1 minute, 72°C for 1 minute and a
last extension at 72°C for 7 minutes. PCR products were
analyzed on a 2% agarose gel stained with 0.5 μg/mL eth-
idium bromide. The GSTT1, GSTM1 and BCL2 produce
480 bp, 219 bp and 154 bp respectively. The presence of
BCL2 without GSTT1 or GSTM1 reflects their deletion.
Statistical analysis
Logistic regression was used to assess the risk between
GSTT1 and GSTM1 null genotypes and the occurrence
of CML. Odds ratio (OR) with a confidence interval (CI)
of 95% was calculated. The chi-square test was used to
compare the genotype distribution between patients and
control. A p-value less than 0.05 was considered as sta-
tistically significant. We have used the statistical package
SPSS version 16 (SPSS Inc., Chicago, IL, USA).
Results
In this case-control study, we explored the frequency of
GSTM1 and GSTT1 genotypes in 92 CML patients and
93 controls. The patients were composed of 34 males
(37%), 58 females (63%) with a mean age of 40.62 ± 12.7;
range (18-76 years). However, the control was composed
of 39 males (41.9%), 54 females (58.1) with a mean age
of 41.38 ± 13.4; range (18-77). The frequencies of
GSTM1 and GSTT1 genotypes between patients and
control are summarized in Table 1. We found that the
GSTM1 null genotype was moderately more frequent in
patients (48.9%) compared to control (40.9%), however,
this difference was not statistically significant (OR 95%
CI, 1.4, 0.78-2.48; p = 0.271). This observation has
remained valid for the GSTT1 null genotype with a fre-
quency of 17.4% in patients against 9.7% in the control
group (OR 95% CI, 1.97, 0.82-4.71; p = 0.13) (Table 1).
The combination of both polymorphisms shows that
Table 3 Effect of GSTM1 and GSTT1 genotypes on the
development of CML in males
GST polymorphism Patients Control OR P value
N (%) N (%) 95% CI
GSTM1
Present 16 (47.1) 25 (64.1) 1
Null 18 (52.9) 14 (35.9) 2 (0.79-5.14) 0.145
GSTT1
Present 24 (70.6) 36 (92.3) 1
Null 10 (29.4) 3 (7.7) 5 (1.25-20.1) 0.023
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associated with a limited effect (OR 95% CI, 0.3, 0.08-
0.99; p = 0.049). Other types of combination showed no
trend. The dual deletion which corresponds to GSTM1
null and GSTT1 null genotypes has been observed in 6
patients 6.5% against 5 control 5.4% Table 2. Surpris-
ingly, the distribution of participants based on gender
revealed that the GSTT1 null genotype is associated with
the development of CML in males (OR 95% CI, 5, 1.25-
20.1; p = 0.023) (Table 3). However, in females the
GSTM1 and GSTT1 null genotypes did not appear to be
associated with the occurrence of CML (Table 4).
Discussion
The development of cancer results from an imbalance
between exposure to carcinogens (endogenous and ex-
ogenous) and the capacity of various enzyme systems
engaged in activation or in the detoxification of xenobi-
otics (Kawajiri et al. 1993). Interindividual genetic vari-
ation in xenobiotics metabolizing enzymes has been
associated with cancer development (Taningher et al.
1999). Nowadays, many epidemiological studies have
shown the implication of GSTM1 and GSTT1 poly-
morphism in tumorigenesis such as CML (Fang et al.
2013; Duggan et al. 2013).
In the current study, the GSTM1 null genotype fre-
quency (40.9%) was comparable to that observed in Cau-
casians and Asians (40-62%) but higher than that
observed in African-Americans ((16-36%). However, the
frequency of GSTT1 null genotype (9.7%) in our popula-
tion showed a similar trend to that observed in Cauca-
sians (10-26%) but was less than that observed in Asians
(35-52%) (Garte et al. 2001; Van der Logt et al. 2004).
The frequency of the homologous deletion (GSTM1 and
GSTT1 null genotypes), synonymous of absence of en-
zyme activity was less than that observed in Caucasians
(5.4% vs. 10.4%) and that of the Asian population (5.4%
vs. 24.6%) (Garte et al. 2001). Trends in variability of
GSTM1 and GSTT1 null genotypes within a given popu-
lation might help to estimate the risk of subjects in the
development of certain cancers.
In the current study, we noticed that the GSTM1 null
genotype was slightly higher in patients (48.9%) than inTable 2 Risk assessment of CML between different
combinations of GSTM1 and GSTT1 genotypes
GSTM1 GSTT1 Patients Control OR P value
N (%) N (%) 95% CI
Present Present 37 (40.2) 51 (54.8) 1
Present Null 10 (10.9) 4 (4.3) 0.3 (0.08-0.99) 0.049
Null Present 39 (42.4) 33 (35.5) 0.61 (0.33-1.15) 0.128
Null Null 6 (6.5) 5 (5.4) 0.61 (0.17-2.13) 0.434control (40.9%); however, it was not associated with an
increased risk to develop CML (OR 95% CI, 1.4, 0.78-
2.48; p = 0.271) (Table 1). Furthermore, the estimation of
CML risk, according to the gender of participants
showed similar trends in males (OR 95% CI, 2, 0.79-
5.14; p = 0.145) (Table 3) as well as in females (OR 95%
CI, 1.01, 0.52-2.3; p = 0.823) (Table 4). Similar findings
were observed in India with (OR 95% CI, 1.32, 0.73-2.40;
p = 0.4295) (Bhat et al. 2012). Özten et al. 2012, also found
no association between GSTM1 null genotype and CML
(OR 95% CI, 1.11; 0.69-1.80; p = 0.714). A meta-analysis
realized with a large number of participants confirmed
these results (Zintzaras 2009). The analyze of these differ-
ent results shows that GSTM1 null genotype seems not to
be associated with the development of CML.
Overall, the GSTT1 null genotype was not found to be
associated with the development of CML when males
and females were pooled together (OR 95% CI, 1.97;
0.82-4.71; p = 0.13) (Table 1). A study carried in Japan,
also failed to find any association between GSTT1 null
genotype and CML (Hishida et al. 2005). Surprisingly, in
considering participants according to gender, we have
found a significant association between GSTT1 null geno-
type and CML in males (OR 95% CI, 5; 1.25-20.1; p =
0.023) (Table 3) but not in females (OR 95% CI, 0.9; 0.28-
3.06; p = 0.896) (Table 4). This finding might be explained
by differences in xenobiotics exposure between males and
females (e.g. Smoke, pesticides) or other genetic/nonTable 4 Effect of GSTM1 and GSTT1 genotypes on the
development of CML in females
GST polymorphism Patients Control OR P value
N (%) N (%) 95% CI
GSTM1
Present 31 (53.4) 30 (55.6) 1
Null 27 (46.6) 24 (44.4) 1.01 (0.52-2.3) 0.823
GSTT1
Present 52 (89.7) 48 (88.9) 1
Null 6 (10.6) 6 (11.1) 0.9 (0.28-3.06) 0.896
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study reported an association between GSTT1 null geno-
type and CML (OR 95% CI, 2.82; 1.58-5.05; p < 0.001)
(Taspinar et al. 2008). Another study done in India, also
found that GSTT1 null genotype was associated with the
development of CML (OR 95% CI, 2.67; 1.03-7.01) (Bajpai
et al. 2007).
The combined GSTM1 present/GSTT1 null genotype
was found to have a limited effect against the develop-
ment of CML when compared to GSTM1 present/
GSTT1 present genotype (OR 95% CI, 0.3, 0.08-0.99; p =
0.049). Anyway, this finding shows a marginal inter-
action, between GSTM1 and GSTT1 genes. (Zintzaras
2009) has reported a significant association between
GSTM1 present/GSTT1 null genotype and CML. Else-
where, we found that the GSTM1 null/GSTT1 null geno-
type was not associated with the development of CML
when compared to GSTM1 present/GSTT1 present
genotype (OR 95% CI, 0.61, 0.17-2.13; p = 0.434). In con-
trast, other authors have found that GSTM1 null/GSTT1
null genotype exposed significantly subjects to develop
CML when compared to GSTM1 present/GSTT1 present
genotype (Bhat et al. 2012; Özten et al. 2012), some au-
thors, reported that subjects with GSTM1 present/GSTT1
null genotype were 2.5 times more likely to develop CML
when compared to GSTM1 null/GSTT1 present genotype
(Özten et al. 2012). The results from these authors show a
possible interaction between GSTM1 and GSTT1.
Conclusion
To the best our knowledge, this is the first study on a
Moroccan population, assessing the risk of GSTM1 and
GSTT1 null genotype carriers in the development of
CML. This study has allowed to determine the frequency
of GSTM1 and GSTT1 polymorphism in a sample of our
population. In addition, we have noted that the GSTT1
null genotype is associated with the development of
CML in males but not in females.
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